ReviewCureus2025
The Use of Hyaluronic Acid in the Treatment of Unilateral Vocal Fold Paralysis: A Systematic Review and Meta-Analysis.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comprehensive single-cell analysis reveals cellular heterogeneity and immune interactions in colorectal cancer.Translational oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Unilateral vocal fold paralysis (UVFP) is a neurological condition characterized by glottal insufficiency, commonly resulting from iatrogenic damage sustained during head and neck surgery. Hyaluronic acid (HA), a naturally occurring glycosaminoglycan, has been shown to influence vocal cord function positively. This study aimed to evaluate the effectiveness of HA in treating UVFP. A systematic review and meta-analysis were conducted following the PRISMA guidelines (PROSPERO ID: CRD42024560084). Literature searches were performed in PubMed, Cochrane Library, Web of Science, and Google Scholar up to August 2024 using a comprehensive combination of terms related to HA and UVFP. Two independent reviewers conducted study selection, data extraction, and quality appraisal using the Newcastle-Ottawa Scale for observational studies and the Cochrane Risk of Bias tool for randomized controlled trials. Thirty-two studies involving 1,917 adult patients were included. Outcomes assessed included quality of life (QOL), maximal phonation time (MPT), and normalized glottal gap area (NGGA). Meta-analysis demonstrated significant short- and medium-term improvements in patient-reported QOL following HA injection (standardized mean difference [SMD]=0.87, 95% CI [0.65-1.09]; p < 0.0001; I²=0%). Medium-term MPT also improved significantly (SMD=0.45, 95% CI [0.16-0.74]; p=0.003; I²=2%). Similarly, NGGA improved in the medium term (SMD=0.51, 95% CI [0.19-0.83]; p=0.002; I²=0%). Adverse events were rare and mostly minor, including transient dysphonia and inflammation. The overall risk of bias was low in most included studies. HA injection laryngoplasty appears effective in improving vocal function and quality of life in patients with UVFP in the short to medium term. However, the current evidence is limited by variable follow-up durations, technique heterogeneity, and insufficient long-term data. Future studies should explore patient-specific outcomes, standardized intervention protocols, long-term efficacy, and safety across diverse populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.